Effectiveness of Association Mometasone Furoate 0.1% and Salicylic Acid 5% Compared With Mometasone Furoate

Plaque Psoriasis Clinical Trial

— Psoriasis  

Official title:

CLINICAL EVALUATION OF EFFECTIVENESS OF ASSOCIATION MOMETASONE FUROATE 0.1% AND SALICYLIC ACID 5% COMPARED WITH 0.1% MOMETASONE FUROATE INSULATED TOPICAL USE OF LABORATORY Glenmark Pharmaceuticals Ltd, IN PATIENTS WITH PSORIASIS IN PLATE

Clinical Trial Details — Status: Suspended

Administrative data

• NCT number: NCT01228656
• Other study ID #: SALMOGLEN10906
• Secondary ID: Psoriasis
• Status: Suspended
• Phase: Phase 2
• Start date: September 2006
• Est. completion date: October 2011

Study information

• Verified date: November 2022
• Source: Azidus Brasil
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aims is to evaluate the efficacy and comparative isolation of the association Mometasone furoate + Salicylic Acid and the substance isolated Mometasone furoate produced by the Laboratory Glenmark Pharmaceuticals Ltd. in patients of both sexes, patients with plaque psoriasis grade mild to moderate.

Description:

The specific objective is to evaluate through analytical propedeutics medical improvement in clinical signs and symptoms related to plaque psoriasis. The study will be conducted with 40 patients who will deal with two symmetrical lesions of his body being identified by the clinician that a party should be treated in a double-blind only with mometasone furoate cream containing 0.1% and another with the combination of furoate of mometasone 0.1% + Salicylic Acid 5%. The group of patients to be treated must be adults of both sexes, aged 18-70 years with good mental and physical health to sign the Informed Consent and who are clinically assessed by dermatologists in the study as having mild plaque psoriasis and moderate. The association made a proposal of effectiveness was developed and is produced by the Laboratory Glenmark Pharmaceuticals Ltd., as well as its isolated version of the pilot (mometasone furoate 0.1%). This study should be characterized as Phase II multicenter not.

Recruitment information / eligibility

• Status: Suspended
• Enrollment: 40
• Est. completion date: October 2011
• Est. primary completion date: October 2010
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Adults of both sexes, regardless of color or social class;

• Age 18 or older, with good mental health;

• Patients with plaque psoriasis of mild to moderate;

• Patients who agree to participate and sign the Informed Consent and

• Clarified (appendix);

• Patients who agree to return for follow-up visits.

Exclusion Criteria:

• Patients who are making use of biologics, steroids or steroidal anti-inflammatory and non-steroidal or who made use of these topical medications until 15 days ago 30 days ago or when occurred in oral administration;

• Patients who are exposing themselves to the sun 15 days before the study began or during the course of the same.

• Patients who are making use of acetaminophen;

• Patients who do not agree to the terms described in the informed consent Informed Consent;

• Patients who also have psoriatic plaques of skin disorders caused by fungi or bacteria and who are making use of antimycotics or antibiotics;

• Lions and other types of skin damage than those psoriasis;

• Pregnant and nursing women;

• Patients using oral anticoagulants.

Related Conditions & MeSH terms

• Plaque Psoriasis
• Psoriasis

Intervention

Drug:
• mometasone furoate + salicylic acid
Dermatologic ointment applied once a day.
• Mometasone furoate
Dermatologic ointment applied once a day

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Azidus Brasil

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluating the effectiveness and comparative isolation of the association mometasone furoate + salicylic acid and the substance isolated mometasone furoate		2 months of treatment.
Secondary	Evaluation by means of analytical propedeutics medical improvement in clinical signs and symptoms related to plaque psoriasis.		2 months of treatment.